Pre - PA Allowance

None

Prior-Approval Requirements

Age 18 years of age or older

Diagnosis

Patient must have the following:

Newly-diagnosed acute myeloid leukemia (AML)

AND ALL of the following:

- 1. Used in combination with low-dose cytarabine
- 2. Patient is 75 years of age or older **OR** patient has comorbidities that preclude the use of intensive induction chemotherapy
- 3. Prescriber agrees to monitor electrocardiograms (ECGs) for QTc prolongation
- Prescriber agrees to advise females of reproductive potential to use effective contraception during treatment and for at least 30 days after the last dose
- Prescriber agrees to advise males with female partners of reproductive potential to use condoms during treatment and for at least 30 days after the last dose

Prior - Approval Limits

Quantity

Strength	Quantity Limit
25 mg tablets	180 tablets per 90 days OR
100 mg tablets	90 tablets per 90 days

Duration 12 months

Prior - Approval Renewal Requirements

Age 18 years of age or older

Diagnosis



DAURISMO (glasdegib)

Patient must have the following:

Acute myeloid leukemia (AML)

AND ALL of the following:

- 1. Used in combination with low-dose cytarabine
- 2. NO disease progression or unacceptable toxicity
- 3. Prescriber agrees to monitor electrocardiograms (ECGs) for QTc prolongation
- 4. Prescriber agrees to advise females of reproductive potential to use effective contraception during treatment and for at least 30 days after the last dose
- Prescriber agrees to advise males with female partners of reproductive potential to use condoms during treatment and for at least 30 days after the last dose

Prior - Approval Renewal Limits

Same as above